KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DIAB-A22-1 is expected to begin on schedule today. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol ("CBD") may… Read More..

Conference Call will be Tuesday, November 15th at 10:30am ET / 9:30am CT DALLAS, November 08, 2022--(BUSINESS WIRE)--Blackboxstocks Inc. (NASDAQ: BLBX), a financial technology and social media hybrid platform offering real-time proprietary analytics for stock and options traders of all levels, today announced that the Company will hold a quarterly… Read More..

Final Study Results are Expected in First Half of 2023 TARRYTOWN, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today announced that… Read More..